Can immune profiling unlock the hidden stages of tuberculosis?
NCT ID NCT07735754
First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time
Summary
This study aims to better understand tuberculosis (TB) across its entire spectrum—from early, symptom-free infection to active disease and after treatment. Researchers will recruit TB patients and their close contacts to analyze immune responses and identify biomarkers that could predict infection risk, disease progression, and treatment success. The goal is to develop innovative tools for managing all phases of TB.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to better tools for detecting and managing tuberculosis at all stages, potentially reducing transmission and improving treatment outcomes.
- What could go wrong
- This is an observational study, so it will not test a new treatment. The findings may not directly translate into clinical practice without further research.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE RESPIRATORY INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple CT scan catch lung cancer earlier in kuwait?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Your Tumor's DNA might predict immunotherapy success
- Can a new PET tracer light up hidden cancers?
- Fellow veterans may hold the key to earlier lung cancer detection